APGE
Price
$40.12
Change
+$0.92 (+2.35%)
Updated
May 2 closing price
Capitalization
2.34B
15 days until earnings call
ERAS
Price
$1.58
Change
+$0.09 (+6.04%)
Updated
May 2 closing price
Capitalization
447.59M
4 days until earnings call
Ad is loading...

APGE vs ERAS

Header iconAPGE vs ERAS Comparison
Open Charts APGE vs ERASBanner chart's image
Apogee Therapeutics
Price$40.12
Change+$0.92 (+2.35%)
Volume$616.31K
Capitalization2.34B
Erasca
Price$1.58
Change+$0.09 (+6.04%)
Volume$1.31M
Capitalization447.59M
APGE vs ERAS Comparison Chart
Loading...
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APGE vs. ERAS commentary
May 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APGE is a Buy and ERAS is a Buy.

Ad is loading...
COMPARISON
Comparison
May 04, 2025
Stock price -- (APGE: $40.12 vs. ERAS: $1.58)
Brand notoriety: APGE and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APGE: 86% vs. ERAS: 74%
Market capitalization -- APGE: $2.34B vs. ERAS: $447.59M
APGE [@Biotechnology] is valued at $2.34B. ERAS’s [@Biotechnology] market capitalization is $447.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APGE’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • APGE’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both APGE and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APGE’s TA Score shows that 6 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • APGE’s TA Score: 6 bullish, 4 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both APGE and ERAS are a good buy in the short-term.

Price Growth

APGE (@Biotechnology) experienced а +8.87% price change this week, while ERAS (@Biotechnology) price change was +13.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

APGE is expected to report earnings on May 19, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APGE($2.34B) has a higher market cap than ERAS($448M). APGE YTD gains are higher at: -11.435 vs. ERAS (-37.052). ERAS has higher annual earnings (EBITDA): -151.33M vs. APGE (-216.68M). APGE has more cash in the bank: 521M vs. ERAS (319M). APGE has less debt than ERAS: APGE (11.8M) vs ERAS (52.9M). APGE (0) and ERAS (0) have equivalent revenues.
APGEERASAPGE / ERAS
Capitalization2.34B448M523%
EBITDA-216.68M-151.33M143%
Gain YTD-11.435-37.05231%
P/E RatioN/AN/A-
Revenue00-
Total Cash521M319M163%
Total Debt11.8M52.9M22%
TECHNICAL ANALYSIS
Technical Analysis
APGEERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
79%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
View a ticker or compare two or three
Ad is loading...
APGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTSIX29.320.70
+2.45%
Invesco Small Cap Growth Inv
FDGKX37.090.69
+1.90%
Fidelity Dividend Growth K
JDVRX21.790.39
+1.82%
PGIM Jennison Value R
MPDGX9.550.15
+1.60%
MassMutual Disciplined Gr R4
RYDKX90.211.22
+1.37%
Rydex Dow Jones Industrial Average® C

APGE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APGE has been loosely correlated with SYRE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if APGE jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APGE
1D Price
Change %
APGE100%
+2.35%
SYRE - APGE
52%
Loosely correlated
+3.07%
ELVN - APGE
51%
Loosely correlated
+3.32%
ATXS - APGE
51%
Loosely correlated
+3.88%
CRNX - APGE
48%
Loosely correlated
+0.72%
ERAS - APGE
47%
Loosely correlated
+6.04%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+6.04%
XNCR - ERAS
54%
Loosely correlated
+3.68%
RVMD - ERAS
52%
Loosely correlated
+0.20%
KYMR - ERAS
51%
Loosely correlated
+2.11%
BEAM - ERAS
50%
Loosely correlated
+2.07%
ELVN - ERAS
50%
Loosely correlated
+3.32%
More